Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 477Neoplasms 292Breast Neoplasms 281Colorectal Neoplasms 223Neoplasm Metastasis 188Prostatic Neoplasms 168Ovarian Neoplasms 166Lung Neoplasms 155Multiple Myeloma 153Recurrence 132Melanoma 116Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 105Endometrial Neoplasms 99Stomach Neoplasms 98Leukemia, Myeloid, Acute 97Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Triple Negative Breast Neoplasms 81Lymphoma, Non-Hodgkin 81Carcinoma, Renal Cell 80Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 76Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 64Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cancer Cachexia × 90 days × Clear all
NCT07584057 2026-05-13

An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia

Yunnan Baiyao Group Co., Ltd.

Phase 1/2 Not yet recruiting
146 enrolled

Cancer Cachexia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡